- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01797107
Study to Determine the Effect of Azasite on Corneal Surface Irregularity
A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effect of Azasite on Corneal Surface Irregularity in Subjects With Meibomian Gland Dysfunction
Study Overview
Detailed Description
This will be a single-center, randomized, vehicle-controlled, double-masked, clinical trial comparing a four week course of Azasite (azithromycin ophthalmic 1%) to vehicle (Durasite®) in patients with MGD-related evaporative dry eye. All patients will be evaluated at screening, baseline, two weeks, four weeks, and six weeks.
The primary outcome measure will be improvement, as compared to baseline, in corneal irregularity as measured by a topographically-derived value, the Corneal Irregularity Measurement (CIM). Secondary outcome measures will be a global symptom score, tear film break up time, meibomian gland secretion characteristics, best-corrected distance visual acuity, corneal staining, axial topography based astigmatism patterns, and IOL Master keratometry.
We will enroll 60 eyes of 30 patients, and each patient will be randomly assigned to receive Azasite in one eye and vehicle (Durasite®) in the fellow eye.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19148
- Philadelphia Eye Associates
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ability to provide informed consent prior to enrollment in study
- Patient ability to follow study instructions and comply with all study protocols
- Corneal irregularity measurement (CIM) > 1.7 in both eyes
- Non-atrophic meibomian gland dysfunction (MGD) as defined by abnormal meibomian expression in at least 2 meibomian glands of the eyelids of each eye
- At least two symptoms of at least moderate severity (≥ grade 2, 0 to 3 scale) as defined in the MGD Global Symptom Score (Itching, Foreign-body sensation, Dryness, Burning, Lid swelling)
- Tear film break up time < 10 seconds
- Schirmer with anesthesia > 5 mm
- Best corrected distance visual acuity (BCDVA) > 20/100
Exclusion Criteria:
- Cicatricial or atrophic meibomian gland dysfunction (MGD)
- Any corneal disease or scar involving the central 6 mm, including epithelial basement membrane dystrophy, Salzmann nodular degeneration, recurrent erosions, keratoconus or ectasia
- Use of azithromycin or doxycycline within 1 month of screening
- Topical ocular antibiotic, anti-histamines, allergy, or steroid medication within 2 weeks of baseline (a 2 week washout after screening will be allowed)
- Topical prostaglandin analogue use within 30 days of study
- The anticipated use of any drops, gels or ointments during the study period outside of the study protocol
- Use of eye make-up during study period
- Active ocular infection or inflammation
- History of herpetic eye disease or neurotrophic keratitis
- Lid pathology (except MGD or blepharitis) that the examiner feels may affect the ocular surface
- Significant conjunctival scars (ex. h/o SJS)
- Pterygium
- Lacrimal punctal occlusion within 2 months of screening
- Ocular surgery within 1 year of screening
- Monocular patients
- Pregnant, breast-feeding, or sexually active females not using contraception
- Uncontrolled systemic disease
- Presence of any disease (medical or ocular) that, in the opinion of the investigator, may interfere with the study's safety or interpretation
- Known allergy to the study medication or its components
- Current enrollment in an investigational drug or device study within 30 days of screening for this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment eye
Azasite (azithromycin ophthalmic 1%) twice a day for 2 days followed by nightly for 4 weeks
|
Patients will be given 1 drop twice a day for 2 days followed by 1 drop nightly for 4 weeks.
Other Names:
|
Placebo Comparator: Durasite
Vehicle of Azasite used as placebo
|
Patients will be given 1 drop twice a day for 2 days followed by 1 drop nightly for 4 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Corneal Irregularity Measurement
Time Frame: 4 weeks
|
Topographically defined corneal smoothness as compared to baseline measurement at day 0
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Global symptoms score
Time Frame: 2,4 and 6 weeks
|
0-3 score of itching, foreign body sensation, dryness, burning and swelling as compared to baseline measurement at day 0
|
2,4 and 6 weeks
|
Meibomian gland secretion characteristics
Time Frame: 2, 4 and 6 weeks
|
Meibum secretions of the eyelids will be assessed at each visit by pressing on the lower or upper lid (with a finger) until excretions are seen from at least 2 meibomian glands. The following scale, based on a scale in a study by Mathers et al (Mathers et al. Meibomian Gland Dysfunction in Chronic Blepharitis. Cornea .1991;10(4): 277-285.) will be used: NE= <2 glands expressible = Atrophic or Cicatricial MGD (exclusion at Visit 1 and 2) 0= clear secretion (normal)
|
2, 4 and 6 weeks
|
Best corrected distance visual acuity
Time Frame: 2, 4 and 6 weeks
|
as compared to baseline measurement at day 0
|
2, 4 and 6 weeks
|
Corneal staining
Time Frame: 2, 4 and 6 weeks
|
Using NEI industry workshop scale.
Scores will be compared to baseline measurement at day 0
|
2, 4 and 6 weeks
|
Axial topography based astigmatism pattern
Time Frame: 2, 4 and 6 weeks
|
Patterns will be compared to baseline at day 0. All topography testing will be performed using the same machine and system, the Carl Zeiss Meditec Atlas, Model 9000, system 3.0.0.39. The topographic pattern will be reviewed by a masked investigator (masked to eye randomization), and categorized as one of the following:
|
2, 4 and 6 weeks
|
Intraocular Lens(IOL) Master Keratometry
Time Frame: 2, 4 and 6 weeks
|
As compared to baseline at day 0.
|
2, 4 and 6 weeks
|
Change in Corneal Irregularity Measurement
Time Frame: 2 weeks, 6 weeks
|
Topographically defined corneal smoothness as compared to baseline measurement at day 0
|
2 weeks, 6 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tear film break-up time
Time Frame: 2, 4 and 6 weeks
|
Fluorescein break up time
|
2, 4 and 6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Brad H Feldman, MD, Philadelphia Eye Associates
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 40958
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Meibomian Gland Dysfunction
-
Hovione Scientia LimitedCompletedMeibomian Gland Dysfunction | MGD-Meibomian Gland DysfunctionUnited States
-
University of WaterlooCompletedMeibomian Gland Dysfunction (MGD)Canada
-
Aier School of Ophthalmology, Central South UniversityUnknownMeibomian Gland Massage is Important to Delay the Development of Meibomian Gland DysfunctionChina
-
Second Affiliated Hospital, School of Medicine,...Aier Eye Hospital, WuhanCompletedMGD-Meibomian Gland DysfunctionChina
-
Barzilai Medical CenterCompletedMGD-Meibomian Gland DysfunctionIsrael
-
Singapore National Eye CentreNational University, SingaporeCompleted
-
Johnson & Johnson Surgical Vision, Inc.CompletedCataracts | Meibomian Gland Dysfunction (MGD)United States
-
Azura OphthalmicsThe University of New South WalesCompletedMeibomian Gland Dysfunction (MGD) | Contact Lens Discomfort (CLD)Australia
-
Zhongnan HospitalRecruitingDry Eye | MGD-Meibomian Gland DysfunctionChina
-
Zhongnan HospitalRecruitingDry Eye | Positron-Emission Tomography | MGD-Meibomian Gland DysfunctionChina
Clinical Trials on Azasite
-
Merck Sharp & Dohme LLCCompletedBlepharitisUnited States
-
Merck Sharp & Dohme LLCCompletedBacterial ConjunctivitisUnited States
-
Merck Sharp & Dohme LLCCompletedBlepharitisUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedBlepharitisUnited States
-
Sun Pharmaceutical Industries LimitedWithdrawn
-
Sun Pharmaceutical Industries LimitedCompleted
-
University of LouisvilleCompleted
-
Merck Sharp & Dohme LLCCompletedBacterial ConjunctivitisUnited States
-
Beijing Tongren HospitalZhuhai Essex Bio-Pharmaceutical Company Limited; Panacea TechnologiesUnknownBacterial ConjunctivitisChina